<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903523</url>
  </required_header>
  <id_info>
    <org_study_id>970</org_study_id>
    <nct_id>NCT03903523</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lumen Apposing Metal Stents</brief_title>
  <acronym>LAMS</acronym>
  <official_title>Efficacy and Safety of Lumen Apposing Metal Stents: a Retrospective Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic ultrasonography (EUS) has revolutioned the management of gastroenterological
      patients and is acquiring an increasingly important role.

      The development of specifically designed stents has significantly increased the technical and
      clinical success rate of the EUS-guided procedures, considerably reducing the rate of adverse
      events. Currently EUS has a prominent role in drainage of peripancreatic fluid collections
      and it represents an important therapeutic option for patients with distal malignant biliary
      obstruction, in which the ERCP fails, allowing the positioning of a transgastric or
      transbulbar lumen apposing metal stent (LAMS) to drain the biliary duct. Moreover, the
      EUS-guided gallbladder drainage of patients with high surgical risk and acute cholecystitis,
      which cannot be operated, is another important therapeutic indication.

      Our aim is to perform a multicentre retrospective analysis of all types of EUS drainage
      (gallbladder drainage, biliary drainage, peripancreatic fluid collection drainage) with the
      positioning of LAMS in order to evaluate the rate of technical and clinical success and to
      assess the safety profile of these procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the rate of technical and clinical success of EUS drainage (gallbladder drainage, biliary drainage, peripancreatic fluid collection drainage) with the positioning of lumen apposing metal stents</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Biliary Obstruction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lumen apposing metal stent (LAMS)</intervention_name>
    <description>Stent positioning</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective analysis of a prospectively maintained database of all consecutive patients
        with distal malignat biliary obstruction, high surgical risk acute cholecystitis, or
        symptomatic pancreatic fluid collection that underwent EUS drainage from January 2016 to
        December 2022. All EUS drainage were performed by experienced operators.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  Patients with distal malignant common bile duct obstruction with failed ERCP

          -  Patients with symptomatic peripancreatic fluid collections

          -  Patients with acute cholecystitis who are unfit for surgery

          -  Agree to receive follow up phone calls

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Coagulation and/or platelets hereditary disorders.

          -  Pregnant women

          -  Inability to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Anderloni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Anderloni, MD</last_name>
    <phone>0039-02-82247308</phone>
    <email>andrea.anderloni@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Fugazza, MD</last_name>
    <phone>0039-02-82247021</phone>
    <email>alessandro.fugazza@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+39282247493</phone>
      <email>alessandro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Carrara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Anderloni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milena Di Leo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Anderloni, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

